Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Highly efficient and eco-innovative probiotic food supplement for antibiotic-associated disorders prevention

Objective

Development of novel probiotic solutions for specific illnesses and health problems, ex: Obesity, Depression, Crohn or Colitis diseases.

The solutions proposed by MyBiotics will use Mycrobe TM a delivery technology to overpass the biologic barriers :gastric acid, pancreatic juice and bile salts, and deliver sufficient quantity of living probiotic directly to colonize the gastro intestinal tract were they are therapeutically efficient.

MyBiotics will design for each targeted disease a set of specific bacteria and validate their selection by using MycrobeTM as leverage to provide unreached comfort and easy variation during the selection and test of the probiotics.

The ambition is to provide pharmabiotic solutions for specific diseases and provide robust clinical results for lobbying activities with the EMA, EFSA and FDA for the regulation

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-SMEInst-2014-2015

See all projects funded under this call

Coordinator

MYBIOTICS PHARMA LTD
Net EU contribution
€ 50 000,00
Address
5 GOLDA MEIR BLVD, RTH FLOOR
7414001 Ness Ziona
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00